NCT00001564View on ClinicalTrials.gov

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 23, 1996

Primary Completion Date

October 25, 2007

Study Completion Date

October 25, 2007

Conditions

Ewing's SarcomaRhabdomyosarcoma

Interventions

DRUG

EF-1 Peptide

DRUG

EF-2 Peptide

DRUG

PXFK Peptide

DRUG

E7 Peptide

DRUG

IL-2

DRUG

IL-4

DRUG

GM-CSF

DRUG

CD40 Ligand

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00001564 - A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas | Biotech Hunter | Biotech Hunter